Sedation Management

Introduction to Sedation

• Sedation management aims to keep patients arousable, with the goal of achieving a target level of sedation, typically measured by the RASS score, to minimize side effects, as recommended by the American Gastroenterological Association and the American Society of Anesthesiologists 1, 2, 3, 4

Pharmacological Interventions

• Dexmedetomidine is the sedative infusion with the lowest risk for delirium in critically ill patients compared to benzodiazepines and propofol, based on high-quality evidence from the American Society of Anesthesiologists 5, 1, 2
• Dexmedetomidine significantly reduces delirium incidence compared to benzodiazepines, with a ~20% daily reduction in delirium prevalence, as recommended by the Society of Critical Care Medicine 2
• The characteristics of sedatives are summarized in the following table:

1, 2, 6

• The Society of Critical Care Medicine recommends against using propofol to improve sleep in critically ill adults, due to its association with REM sleep suppression and higher delirium risk than dexmedetomidine, with a conditional recommendation 1
• Avoid benzodiazepines as first-line agents due to increased risk of delirium, prolonged ventilation, and worse outcomes, as recommended by the American College of Critical Care Medicine and the British Medical Journal 1, 7

Sedation Assessment and Management

• Regular assessment of sedation level using validated scales, such as the RASS or Ramsay, is crucial for effective sedation management, as recommended by the American Society of Anesthesiologists 2, 3
• Target light sedation (patient arousable and able to follow simple commands) rather than deep sedation, as suggested by the Society of Critical Care Medicine 2

Dexmedetomidine Administration

• The usual dose of dexmedetomidine for procedural sedation is 1 μg/kg as a loading dose, followed by an infusion of 0.2 μg/kg/h, with a loading dose administered in 10 minutes and a maintenance dose of 0.2 μg/kg/h, as recommended by the American Society of Anesthesiologists 4
• Hemodynamically unstable patients should avoid loading dose and start with lower maintenance doses of dexmedetomidine, as recommended by the European Heart Journal and the American Society of Anesthesiologists 2, 8, 3
• Dexmedetomidine has a biphasic cardiovascular effect, with a transient increase in blood pressure after a 1 μg/kg bolus, followed by a 10-20% decrease in blood pressure due to inhibition of central sympathetic flow, as reported by 4
• Continuous cardiovascular monitoring, including blood pressure and heart rate, is necessary, with special attention to hypotension (21% incidence), bradycardia (10% incidence), and dizziness (26% incidence), as recommended by the American Society of Anesthesiologists 4

Special Considerations

• Dexmedetomidine may cause cardiac effects such as first and second-degree AV blocks, with potential for complete heart block, particularly in patients with cardiac dysfunction or hemodynamic instability, and should be used with caution in these patients, as recommended by the European Heart Journal 9
• Infants have faster clearance of dexmedetomidine compared to adults, suggesting a potentially shorter half-life in the pediatric population 10
• Combination of sedatives can lead to respiratory depression, and management should include having naloxone available, as advised by the American Academy of Pediatrics 11
• Rapid administration of sedatives can cause glottic and chest wall rigidity, as cautioned by the American Academy of Pediatrics 11
• Administration of fentanyl should be done slowly over 2-3 minutes to prevent chest wall rigidity, as recommended by the American Academy of Pediatrics 11